96 Tests PN: A213203
45x Ab-conjugated beads (S4P4 - Mouse sE-selectin Ab-bead). PN: A213203A. One vial containing 100 µL of anti-mouse sL-selectin conjugated to AimPlex Bead S5P11.
25x Biotin-detection Ab (Mouse sE-selectin Biotin-dAb). PN: A213203B. One vial containing 100 µL of biotinylated anti-mouse sL-selectin.
Lyophilized Standard Mix - Mouse Group 5 Panel A, 9-Plex. PN: MG5009A. One vial containing lyophilized recombinant sCD10, sCD14, sICAM, sE-selectin, sL-selectin, sP-selectin, sVCAM, sCD30L, and sCD40L. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human Mouse L-selectin/LECAM1/sCD62L. Can be multiplexed with other analytes in Mouse Group 5. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 20 pg/mL
LLOQ: < 50 pg/mL
ULOQ: > 10,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Mouse Group 5: Negligible
Sample volume: 15 µL/test
E-selectin, also known as CD62 antigen-like family member E (CD62E), endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion molecule 2 (LECAM2), is a cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. During inflammation, E-selectin plays an important part in recruiting leukocytes to the site of injury. The local release of cytokines IL-1 and TNF-α by damaged cells induces the over-expression of E-selectin on endothelial cells of nearby blood vessels. Leukocytes in the blood expressing the correct ligand will bind with low affinity to E-selectin, also under the shear stress of blood flow, causing the leukocytes to "roll" along the internal surface of the blood vessel as temporary interactions are made and broken. E-selectin mediates the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands expressed by neutrophils, monocytes, eosinophils, memory-effector T-like lymphocytes, natural killer cells or cancer cells. E-selectin is also an emerging biomarker for the metastatic potential of some cancers including colorectal cancer and recurrences.
Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, Gimbrone MA, Bevilacqua MP (February 1991). "Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1". J. Biol. Chem. 266 (4): 2466–73. PMID 1703529.
Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK (February 1994). "Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains". Nature 367 (6463): 532–8. doi:10.1038/367532a0. PMID 7509040.
Somers WS, Tang J, Shaw GD, Camphausen RT (October 2000). "Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1". Cell 103 (3): 467–79. doi:10.1016/S0092-8674(00)00138-0. PMID 11081633.
Robbins SL, Cotran RS, Kumar V, Collins T (1999). Robbins pathologic basis of disease. Philadelphia: WB Saunders. ISBN 0-7216-7335-X.
Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M, Maeda K (November 2010). "Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer". Jpn. J. Clin. Oncol. 40 (11): 1073–80. doi:10.1093/jjco/hyq095. PMID 20576794.